STOCK TITAN

Illumina, Inc. - $ILMN STOCK NEWS

Welcome to our dedicated page for Illumina news (Ticker: $ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Illumina's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Illumina's position in the market.

Rhea-AI Summary
The Mining Microbiome Analytics Platform is finding tiny solutions to some of our biggest environmental challenges. The mining industry is on the cusp of a staggering increase in demand for materials critical for low-carbon and renewable energy technology. Teck has built 'saturated rock fills' treated with special bacteria to reduce selenium levels in water. Microbes can also make mining itself more environmentally friendly. The Canadian government's Digital Supercluster initiative has formed the cross-industry Mining Microbiome Analytics Platform (M-MAP) to discover and implement these organisms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
-
Rhea-AI Summary
Illumina included on 2023 list of 100 Best Corporate Citizens
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
-
Rhea-AI Summary
Illumina launches microsite to educate healthcare professionals and promote whole-genome sequencing for genetic diagnosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
none
Rhea-AI Summary
HCA Healthcare and GRAIL collaborate to advance comprehensive cancer care through early detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
-
Rhea-AI Summary
Illumina ordered by the European Commission to divest GRAIL
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Summary
Emma Johnson wins Illumina's Polygenic Risk Scores Research Grant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
none
Rhea-AI Summary
Illumina, Inc. posts stewardship-focused presentation for investors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
none
-
Rhea-AI Summary
A student shares her summer internship experience at Illumina
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary
MassMutual launches Health and Wellness Program to provide policyowners with insights into their health risks and motivate healthy behaviors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
Rhea-AI Summary
GRAIL's PATHFINDER study demonstrates the feasibility of multi-cancer early detection testing, leading to targeted diagnostic evaluations and increased number of new cancers detected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
Illumina, Inc.

Nasdaq:ILMN

ILMN Rankings

ILMN Stock Data

17.14B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.